Coloplast prepares big study of main asset from million-dollar acquisition
After the acquisition of Nine Continents Medical, Coloplast is getting ready to try out the US-based urology firm's main asset against over-active bladder disorder (OAB) in a big clinical trial in the US. The company is expecting to release the results as soon as next year, and hopes for a potential launch in 2024-2025.
BY ULRICH QUISTGAARD, TRANSLATED BY DANIEL PEDERSEN
Coloplast is taking its first step into a new segment of the urology area. The medtech company has just made the final preparations for an extensive clinical study with the company's solution, a "tibial nerve stimulator," for over-active bladder disorder (OAB), the company reports in a press release.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Coloplast expects organic growth of 7 percent next year
For subscribers
